Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

10:45 AM ET 8-K
Capacity Expansion Oppenheimer Holdings Inc OPY

Oppenheimer Holdings Capacity Expansion

Oppenheimer Holdings' subsidiary Viner Finance entered into a 15.5-year lease for approximately 221,339 square feet at 32 Old Slip in Lower Manhattan to serve as its new principal headquarters. The relocation involves a $66 million investment and will house executive management, research, trading, and investment banking operations starting in early 2028. The agreement includes fixed annual rent starting at $13.3 million and provides for significant capital expenditures for technology and infrastructure upgrades.

Counterparty
RXR 32 Old Slip Owner LLC
Term
15.5 years
10:12 AM ET
Earnings Call Ceco Environmental Corp CECO ▶ Call

Ceco Environmental Earnings Call: Key Takeaways

CECO delivered record Q3 results with revenue doubling to $404 million, driven by the Thermon acquisition and 30% organic growth, while providing aggressive 2027 guidance.

Call
Nov 9, 2026, 8:30 AM ET
10:03 AM ET 8-K
Capital Raise Monroe Capital Enhanced Corporate Lending Fund

Monroe Capital Enhanced Corporate Lending Fund Capital Raise

Monroe Capital Enhanced Corporate Lending Fund completed private offerings of Class S and Class D common shares along with promissory notes to 110 accredited investors, raising approximately $152,000 in net proceeds. In connection with these offerings, the Fund reached its minimum shareholder threshold and terminated its existing escrow agreement with U.S. Bank and other parties as the escrow arrangement was no longer required.

Counterparty
110 separate investors
9:49 AM ET 8-K
Clinical Trial Data Oncolytics Biotech Inc ONCY

Oncolytics Biotech Clinical Trial Data

Oncolytics Biotech announced translational data from a Phase 1b/2 trial evaluating pelareorep in patients with relapsed/refractory multiple myeloma. Single-cell sequencing demonstrated that pelareorep engaged the immune system, remodeled the tumor microenvironment, and increased populations of CD8 effector memory T cells. The data, which showed greater T cell expansion in clinical responders, will be presented at the 68th ASH Annual Meeting.

9:23 AM ET 8-K
Capacity Expansion Exascale Labs Holdings Inc. XLAB

Exascale Labs Holdings Capacity Expansion: $9.04M Investment

Exascale Labs Holdings Inc. entered into a firm order to purchase 16 Intel BHS 10U GPU servers equipped with NVIDIA HGX B300 GPUs from Compal Electronics for $9.04 million. The purchase is part of a larger framework agreement allowing the company to acquire up to 128 servers for a total potential value of $72.32 million through March 2027. This acquisition represents a material investment in the company's physical high-performance computing infrastructure.

Value
$9.04M
Counterparty
Compal Electronics, Inc.
Term
through March 31, 2027
9:23 AM ET 8-K
Clinical Trial Data Werewolf Therapeutics, Inc. HOWL

Werewolf Therapeutics Clinical Trial Data

Werewolf Therapeutics announced new clinical data from its Phase 1/1b trial of WTX-124 and Phase 1b/2 trial of WTX-330 for the treatment of solid tumors at the SITC 2026 Annual Meeting. WTX-124 demonstrated durable antitumor activity, including a complete response in a patient with cutaneous squamous cell carcinoma, and the company aligned with the FDA on a recommended Phase 2 dose of 18 mg. WTX-330 was reported as well-tolerated with evidence of monotherapy clinical activity in advanced, treatment-refractory disease.

9:21 AM ET 8-K
Clinical Trial Data Nkarta, Inc. NKTX

Nkarta Clinical Trial Data

Nkarta announced positive initial clinical data from its Ntrust program evaluating NKX019, an allogeneic CAR NK cell therapy, for myositis and systemic sclerosis. In the 4 billion cells per dose cohort, 83% of myositis patients achieved moderate or major responses, while 86% of systemic sclerosis patients achieved an rCRISS-25 response or greater. The therapy demonstrated a favorable safety profile with no cases of CRS, ICANS, or GvHD across 40 treated patients.

9:16 AM ET 8-K
M&A Deal Surgery Partners, Inc. SGRY

Surgery Partners Signs $6B M&A Deal with HealthSpan Partners

Surgery Partners entered into an amendment to its merger agreement with HealthSpan Partners (an affiliate of Bon Secours Mercy Health), increasing the cash consideration to $25.00 per share. The deal includes a 'ticking fee' of up to $1.61 per share if closing is delayed past March 1, 2027, bringing the total enterprise value to approximately $6.0 billion. The amendment follows an unsolicited $28.00 per share competing proposal from a third party, which the board determined was less favorable due to regulatory and closing certainty provided by HealthSpan.

Value
$6B
Counterparty
HealthSpan Partners

“We are pleased to have reached this outcome, which reflects the rigorous focus of our Board of Directors and Special Committee throughout this process on delivering the best possible result for Surgery Partners and our stockholders. This transaction provides exceptional value for our stockholders, along with regulatory certainty and a closing expected in the near term.”

Eric Evans, Chief Executive Officer of Surgery Partners
9:09 AM ET 8-K/A
M&A Deal Fox Corp FOXA

Fox M&A Deal with Roku, Inc.

Fox Corporation completed the acquisition of Roku, Inc. on November 6, 2026, for a combination of cash and FOX Class A Common Stock. This filing provides the required historical financial statements of Roku and pro forma financial information following the consummation of the transaction. Fox expects to realize synergies and operational efficiencies from the integration of Roku's streaming platform into its media business.

Counterparty
Roku, Inc.
9:05 AM ET 8-K
M&A Deal Inflection Point Acquisition Corp. VI IPFX

Inflection Point Acquisition Corp. VI M&A Deal with Quantum Space, LLC

Inflection Point Acquisition Corp. VI provided a status update on its pending merger with Quantum Space, LLC, announcing a Virtual Analyst Day to discuss the company's technology platform and mission pipeline. Upon completion of the business combination, the combined company is expected to list on the NYSE under the ticker symbol QSPC.

Counterparty
Quantum Space, LLC
9:04 AM ET 8-K
Clinical Trial Data Veradermics, Inc MANE

Veradermics Clinical Trial Data

Veradermics announced positive 12-month topline results from Part B of its Phase 2/3 Study '302' evaluating VDPHL01 for male pattern hair loss. The data showed significant increases in non-vellus hair counts and high rates of patient-reported visible improvement with no new safety signals. These results support a potential FDA submission for the first non-hormonal oral treatment for pattern hair loss in nearly 30 years.

Term
12 months
8:46 AM ET 8-K
Clinical Trial Data Faeth Therapeutics, Inc. FTH

Faeth Therapeutics Clinical Trial Data

Faeth Therapeutics announced topline clinical data from its Phase 2 PIK-201 trial evaluating its product candidate PIKTOR in patients with advanced endometrial cancer. The trial evaluated PIKTOR (a combination of serabelisib and sapanisertib) in combination with paclitaxel. The company released a corporate presentation detailing these preliminary efficacy and safety results to investors.

8:40 AM ET 8-K
Capital Raise Innovative Industrial Properties Inc IIPR

Innovative Industrial Properties Capital Raise

Innovative Industrial Properties amended its existing at-the-market (ATM) offering program to add its 9.25% Series B Cumulative Redeemable Preferred Stock to the facility. The program allows for the sale of common and preferred shares with an aggregate offering price of up to $500 million, of which approximately $336.9 million remains available for future issuance.

Counterparty
BTIG, LLC
8:35 AM ET 8-K
Clinical Trial Data Aptevo Therapeutics Inc. APVO

Aptevo Therapeutics Clinical Trial Data

Aptevo Therapeutics presented new preclinical data for its multispecific platform candidates APVO451, APVO452, and APVO711 at the SITC 2026 Annual Meeting. The data demonstrated the molecules' ability to activate immune pathways and promote tumor-cell killing even under immunosuppressive conditions typical of solid tumors. These findings support the continued development of the company's portfolio of CD40-stimulating cancer immunotherapies.

8:31 AM ET 8-K
Clinical Trial Data Vir Biotechnology, Inc. VIR

Vir Biotechnology Clinical Trial Data

Vir Biotechnology announced positive topline results from its pivotal Phase 3 ECLIPSE 1 trial evaluating a combination of elebsiran and tobevibart for chronic hepatitis delta. The trial met its primary endpoint with a 44% response rate (undetectable virus plus ALT normalization) at Week 48 compared to 0% in the delayed treatment group, demonstrating a favorable safety profile with no treatment discontinuations.

8:12 AM ET 8-K
M&A Deal King Resources, Inc. KRFG

King Resources Global Signs $12.3M M&A Deal with Grand View Assets Limited

King Resources Global, Inc., through its subsidiary Heavenly Grace, entered into three purchase agreements to acquire a total of 19 collectible items for an aggregate consideration of approximately $12.34 million. The company will settle the acquisition costs by issuing common stock at a fixed price of $0.235 per share to the seller, Grand View Assets Limited.

Value
$12.3M
Counterparty
Grand View Assets Limited
8:05 AM ET 8-K
M&A Deal InMed Pharmaceuticals Inc. MTRI

InMed Pharmaceuticals Signs $490M M&A Deal with InMed Pharmaceuticals Inc.

Mentari Therapeutics completed its merger with InMed Pharmaceuticals Inc. and began trading on Nasdaq under the ticker 'MTRI'. In connection with the closing, the company completed $490 million in private placement financings to fund its pipeline of migraine prevention biologics, including MT-001 and MT-002.

Value
$490M
Counterparty
InMed Pharmaceuticals Inc.
8:02 AM ET 8-K
Divestiture CNH Industrial N.V. CNH

CNH Industrial Divestiture to Kobelco Construction Machinery Co., Ltd. for $700M

CNH Industrial has entered into a definitive agreement to sell a 70% interest in its Construction Equipment business to Kobelco Construction Machinery for $700 million in cash. The transaction values the business at an enterprise value of $1 billion and transforms CNH into a pure-play agriculture equipment company. CNH will retain a 30% minority interest in the newly formed joint venture entities.

Value
$700M
Counterparty
Kobelco Construction Machinery Co., Ltd.

“This transaction significantly advances CNH’s portfolio simplification and sharpens our focus on agriculture in line with our Path to 2030. As the largest pure-play agriculture machinery OEM, CNH will be better positioned than ever to invest with conviction and create value for farmers, dealers, and shareholders at every point in the cycle.”

Suzanne Heywood, Chair of the CNH Board of Directors

“As the agriculture industry moves toward recovery, this transaction strengthens CNH’s ability to invest in the products and technologies that matter most to farmers. At the same time, by creating a stronger construction equipment player, both CNH and CE JV dealers, along with their customers, will benefit from a suite of high-quality, cost-competitive construction machines that incorporate leading technology.”

Gerrit Marx, Chief Executive Officer of CNH
8:02 AM ET 8-K
M&A Deal Quanome Technologies, Inc. QNME

Quanome Technologies M&A Deal with QAI Labs Ltd.

Quanome Technologies entered into a definitive stock purchase agreement to acquire a 5% equity stake in QAI Labs Ltd., a life sciences technology company developing an AI-enabled antibody discovery platform. In exchange for 31,579 newly issued shares of QAI Labs, Quanome will issue 6,541,236 shares of its own common stock to the seller. The transaction advances Quanome's strategic pillar of applying quantum science and AI to molecular discovery.

Counterparty
QAI Labs Ltd.
8:01 AM ET 8-K
M&A Deal Cvr Energy Inc CVI

Cvr Energy M&A Deal with Marathon Petroleum Corporation

CVR Energy is meeting with potential lenders regarding a proposed Term Loan B secured credit facility to fund a potential acquisition of assets from Marathon Petroleum Corporation. The target assets include the St. Paul Park, Minnesota and Mandan, North Dakota refineries along with associated marketing and logistics assets.

Counterparty
Marathon Petroleum Corporation
8:01 AM ET 8-K
Bankruptcy & Restructuring Childrens Place, Inc. PLCE

Childrens Place Bankruptcy & Restructuring

The Children’s Place, Inc. has voluntarily filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of New Jersey. The company intends to conduct a court-supervised sale of substantially all its assets by the end of December 2026 with the goal of continuing as a going concern. To support operations during this process, the company has entered into a consulting agreement for inventory liquidation sales and plans to secure a new term loan facility from existing lenders.

8:00 AM ET 8-K
M&A Deal CDT Equity Inc. CDT

CDT Equity M&A Deal with Corvus Capital Limited

CDT Equity Inc. received a letter from former CEO Dr. Andrew Regan and Corvus Capital Limited indicating an intent to propose a non-binding acquisition of all outstanding common stock at $2.00 per share. The Board of Directors plans to form a Special Committee of independent directors to evaluate the potential proposal and other strategic alternatives.

Counterparty
Corvus Capital Limited
8:00 AM ET 8-K
Capital Raise Strategy Inc MSTR

Strategy Capital Raise of $284M

Strategy Inc reported that it sold 2,051,348 shares of Class A Common Stock under its at-the-market (ATM) offering program between November 2 and November 8, 2026, generating net proceeds of $283.8 million. The company utilized these proceeds to purchase 1,036 bitcoin for $81.9 million and to repurchase $188.3 million of its STRC preferred stock. As of November 8, 2026, the company holds 850,364 bitcoins acquired at an aggregate purchase price of approximately $64.16 billion.

Value
$284M
8:00 AM ET 8-K
Nasdaq/NYSE Compliance Notice Future Vision II Acquisition Corp. FVN

Future Vision II Acquisition Nasdaq/NYSE Compliance Notice

Future Vision II Acquisition Corp. received notification from Nasdaq on November 5, 2026, confirming that the company has regained compliance with the minimum public holders requirement under Nasdaq Listing Rule 5550(a)(3). Nasdaq has determined the company now complies with the rule and has officially closed the matter.

Counterparty
The Nasdaq Stock Market LLC
7:50 AM ET 8-K
M&A Deal CorMedix Inc. CRMD

CorMedix Signs $145M M&A Deal with Heron Therapeutics, Inc.

CorMedix Inc. has entered into a definitive agreement to acquire substantially all assets of Heron Therapeutics for $145 million in cash and 14,583,333 shares of common stock. The deal adds four commercial-stage products (ZYNRELEF, APONVIE, CINVANTI, and SUSTOL) to CorMedix's institutional care portfolio and includes up to $55 million in potential earn-out payments. To fund the transaction, CorMedix secured a new $75 million senior secured term loan facility from Pharmakon Advisors.

Value
$145M
Counterparty
Heron Therapeutics, Inc.
7:41 AM ET 8-K
Divestiture Heron Therapeutics, Inc. HRTX

Heron Therapeutics Divestiture to CorMedix Inc. for $145M

Heron Therapeutics has entered into a definitive agreement to sell substantially all of its assets to CorMedix Inc. for $145 million in cash and 14,583,333 shares of CorMedix common stock. The deal includes Heron's commercial portfolio (ZYNRELEF, APONVIE, CINVANTI, and SUSTOL) and provides for up to $55 million in potential earn-out payments plus royalties. Heron will remain a standalone public company, using the proceeds to repay its existing debt and evaluate new strategic investments.

Value
$145M
Counterparty
CorMedix Inc.
7:33 AM ET 8-K
Clinical Trial Data Viridian Therapeutics, Inc.\DE VRDN

Viridian Therapeutics, Inc.\DE Clinical Trial Data

Viridian Therapeutics announced positive Phase 1 clinical trial results for VRDN-008, a half-life extended FcRn inhibitor, which demonstrated a 74% peak reduction in IgG and a half-life 5-6 times longer than first-generation fragments. The data supports a potential best-in-class every-eight-week subcutaneous dosing regimen, and the company plans to initiate a pivotal trial in myasthenia gravis in mid-2027.

7:30 AM ET 8-K
Nasdaq/NYSE Compliance Notice Netcapital Inc. NCPL

Netcapital Nasdaq/NYSE Compliance Notice

Netcapital Inc. received an extension from Nasdaq to regain compliance with Listing Rule 5250(c)(1) regarding delinquent periodic reports. The company has been granted until February 9, 2027, to file its Form 10-K for the fiscal year ended April 30, 2026, and its Form 10-Q for the quarter ended July 31, 2026. Failure to meet this deadline will result in a delisting notification, which the company may then appeal.

Counterparty
Nasdaq
Term
through Feb 9, 2027
7:30 AM ET 8-K
Capital Raise Inovio Pharmaceuticals, Inc. INO

Inovio Pharmaceuticals Capital Raise of $80.5M

INOVIO Pharmaceuticals entered into an underwriting agreement for a public offering of 58,747,235 shares of common stock and 12,681,337 pre-funded warrants. The underwriters fully exercised their option to purchase an additional 10,714,285 shares, bringing expected net proceeds to approximately $80.5 million. The capital will be used to support the company's development and commercialization of DNA medicines.

Value
$80.5M
Counterparty
Jefferies LLC and Piper Sandler & Co.
7:21 AM ET 8-K
Clinical Trial Data Cullinan Therapeutics, Inc. CGEM

Cullinan Therapeutics Clinical Trial Data

Cullinan Therapeutics announced positive interim Phase 1b/2a clinical data for velinotamig in patients with refractory systemic lupus erythematosus (SLE). The data showed that 8 of 9 evaluable patients achieved clinically meaningful reductions in disease activity, with 4 of 7 patients with high baseline proteinuria achieving a complete renal response. The therapy demonstrated a favorable safety profile with no Grade 3 or higher cytokine release syndrome or neurotoxicity.

Counterparty
Chongqing Genrix Biopharmaceutical Co., Ltd.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.